MX2021013844A - Anticuerpos biespecificos activables que comprenden un enlazador entre los dos dominios de union, que es una region bisagra de inmunoglobulina humana, o una variante de esta, y usos de estos. - Google Patents

Anticuerpos biespecificos activables que comprenden un enlazador entre los dos dominios de union, que es una region bisagra de inmunoglobulina humana, o una variante de esta, y usos de estos.

Info

Publication number
MX2021013844A
MX2021013844A MX2021013844A MX2021013844A MX2021013844A MX 2021013844 A MX2021013844 A MX 2021013844A MX 2021013844 A MX2021013844 A MX 2021013844A MX 2021013844 A MX2021013844 A MX 2021013844A MX 2021013844 A MX2021013844 A MX 2021013844A
Authority
MX
Mexico
Prior art keywords
linker
variant
human immunoglobulin
hinge region
binding domains
Prior art date
Application number
MX2021013844A
Other languages
English (en)
Inventor
William James Jonathan Finlay
Original Assignee
LockBody Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by LockBody Therapeutics Ltd filed Critical LockBody Therapeutics Ltd
Publication of MX2021013844A publication Critical patent/MX2021013844A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

En la presente se describen moléculas de proteína que presentan unión al objetivo activable en tejidos enfermos y moléculas de ácido nucleico, vectores y células hospedadoras relacionados; también se describen en la presente usos médicos para tales moléculas de proteína.
MX2021013844A 2019-05-13 2020-05-13 Anticuerpos biespecificos activables que comprenden un enlazador entre los dos dominios de union, que es una region bisagra de inmunoglobulina humana, o una variante de esta, y usos de estos. MX2021013844A (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GBGB1906685.1A GB201906685D0 (en) 2019-05-13 2019-05-13 Activatable protein constructs and uses thereof
GBGB1910254.0A GB201910254D0 (en) 2019-05-13 2019-07-17 Activatable protein constructs and uses thereof
GBGB1917678.3A GB201917678D0 (en) 2019-05-13 2019-12-04 Activatable protein constructs and uses thereof
GBGB2001196.1A GB202001196D0 (en) 2019-05-13 2020-01-28 Activatable protein constructs and uses thereof
PCT/EP2020/063362 WO2020229553A1 (en) 2019-05-13 2020-05-13 Activatable bispecific antibodies comprising a linker between the two binding domains which is a human immunoglobulin hinge region, or a variant thereof, and uses thereof

Publications (1)

Publication Number Publication Date
MX2021013844A true MX2021013844A (es) 2022-03-17

Family

ID=67384589

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021013844A MX2021013844A (es) 2019-05-13 2020-05-13 Anticuerpos biespecificos activables que comprenden un enlazador entre los dos dominios de union, que es una region bisagra de inmunoglobulina humana, o una variante de esta, y usos de estos.

Country Status (13)

Country Link
US (1) US20230192899A1 (es)
EP (1) EP3969116A1 (es)
JP (1) JP2022532534A (es)
KR (1) KR20220008841A (es)
CN (1) CN113840634A (es)
AU (1) AU2020276891A1 (es)
BR (1) BR112021022661A2 (es)
CA (1) CA3138827A1 (es)
GB (4) GB201906685D0 (es)
IL (1) IL287890A (es)
MX (1) MX2021013844A (es)
SG (1) SG11202112114YA (es)
WO (1) WO2020229553A1 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MD3652215T2 (ro) 2017-07-14 2021-06-30 Immatics Biotechnologies Gmbh Moleculă polipeptidică îmbunătăţită cu specificitate duală
US11434291B2 (en) 2019-05-14 2022-09-06 Provention Bio, Inc. Methods and compositions for preventing type 1 diabetes
JP2022548310A (ja) * 2019-09-23 2022-11-17 シートムエックス セラピューティクス，インコーポレイテッド 抗ｃｄ４７抗体、活性化可能抗ｃｄ４７抗体、およびその使用方法
WO2021252917A2 (en) 2020-06-11 2021-12-16 Provention Bio, Inc. Methods and compositions for preventing type 1 diabetes
JP2023547499A (ja) * 2020-11-06 2023-11-10 ノバルティス アーゲー 抗体Ｆｃ変異体
MX2023012902A (es) 2021-05-05 2023-11-08 Immatics Biotechnologies Gmbh Proteinas de union a antigenos que se unen especificamente a prame.
MX2024009251A (es) * 2022-01-31 2024-08-06 Centessa Pharmaceuticals Uk Ltd Proteinas biespecificas activables anti-cd47 y anti-pd-l1 y usos de las mismas.
WO2023187130A1 (en) * 2022-03-30 2023-10-05 LockBody Therapeutics Ltd Activatable bispecific anti-cd3 and anti-pd-l1 proteins and uses thereof
WO2023192973A1 (en) * 2022-04-01 2023-10-05 Cytomx Therapeutics, Inc. Activatable multispecific molecules and methods of use thereof
WO2023222580A1 (en) 2022-05-16 2023-11-23 Byondis B.V. Novel masked antibodies
GB202302074D0 (en) * 2023-02-14 2023-03-29 Creasallis Ltd Agents, methods and uses thereof
WO2024218509A1 (en) * 2023-04-19 2024-10-24 Centessa Pharmaceuticals (Uk) Limited Activatable bispecific anti-cd28 and anti pd-l1 proteins and uses thereof
WO2024218512A1 (en) * 2023-04-19 2024-10-24 Centessa Pharmaceuticals (Uk) Limited Activatable bispecific anti-cd89 and anti-pd-l1 proteins and uses thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010037837A2 (en) * 2008-10-01 2010-04-08 Micromet Ag Bispecific single chain antibodies with specificity for high molecular weight target antigens
SI2654780T1 (sl) 2010-12-23 2017-06-30 Janssen Biotech Inc. Aktivni proteazno rezistentni protitelesni mutanti Fc
AU2015323313B2 (en) * 2014-09-25 2021-04-01 Amgen Inc. Protease-activatable bispecific proteins
CN108884144B (zh) * 2016-03-18 2023-03-14 弗雷德哈钦森癌症中心 用于cd20免疫疗法的组合物和方法
BR112018016281A2 (pt) * 2016-03-22 2019-01-02 Hoffmann La Roche molécula biespecífica ativadora de célula t ativável por protease, polipeptídeo idiotipo-específico, composição farmacêutica, usos da molécula biespecífica e método de tratamento de uma doença em um indivíduo
CN111212852A (zh) 2017-08-18 2020-05-29 超人肆有限公司 结合剂
GB201803892D0 (en) 2018-03-12 2018-04-25 Ultrahuman Six Ltd C-met binding agents

Also Published As

Publication number Publication date
GB202001196D0 (en) 2020-03-11
AU2020276891A1 (en) 2021-12-23
WO2020229553A1 (en) 2020-11-19
BR112021022661A2 (pt) 2022-03-29
KR20220008841A (ko) 2022-01-21
JP2022532534A (ja) 2022-07-15
GB201917678D0 (en) 2020-01-15
CA3138827A1 (en) 2020-11-19
CN113840634A (zh) 2021-12-24
US20230192899A1 (en) 2023-06-22
GB201910254D0 (en) 2019-08-28
IL287890A (en) 2022-01-01
EP3969116A1 (en) 2022-03-23
GB201906685D0 (en) 2019-06-26
SG11202112114YA (en) 2021-11-29

Similar Documents

Publication Publication Date Title
MX2021013844A (es) Anticuerpos biespecificos activables que comprenden un enlazador entre los dos dominios de union, que es una region bisagra de inmunoglobulina humana, o una variante de esta, y usos de estos.
WO2019051102A3 (en) Constrained conditionally activated binding proteins
MX2022009306A (es) Loseta de nucleo de espuma densificada (dfc) con linea de anticuerpos de dominio individual de cd28 y constructos multivalentes y multiespecíficas de los mismos.
CY1123400T1 (el) Ανθρωπινα anti-il-23 αντισωματα, συνθεσεις, μεθοδοι και χρησεις
JOP20200313A1 (ar) أجسام مضادة dll3-cd3 ثنائية الخاصية
MX2022000652A (es) Anticuerpos contra claudina 18 y metodos de tratamiento del cancer.
MA54513A (fr) Molécules de liaison à l'antigène cd28 agonistes de ciblage de tumeurs
WO2020076977A3 (en) Dll3 single domain antibodies and therapeutic compositions thereof
EP4039710A3 (en) Anti-cd3 antibodies, anti-cd123 antibodies and bispecific antibodies specifically binding to cd3 and/or cd123
PE20210844A1 (es) Contorsbodies 2 + biespecificos
MX2020002921A (es) Anticuerpos para claudin6 y métodos para tratar el cáncer.
AU2018271872A1 (en) A protein binding NKG2D, CD16 and ROR1 or ROR2
WO2016057769A3 (en) Glycoengineered antibody drug conjugates
JOP20190187A1 (ar) مترافقات عقار جسم مضاد لـ ccr7
WO2003033654A3 (en) Direct targeting binding proteins
MX2021011330A (es) Anticuerpos de claudina-6 y conjugados de fármacos.
MX2022007849A (es) Anticuerpos especificos contra la claudina 18.2 tumoral.
PH12020500137A1 (en) Antigen binding proteins binding to 5t4 and 4-1bb and related compositions and methods
WO2020076969A3 (en) Anti-lap antibody variants and uses thereof
AU2019433019A8 (en) Antibodies binding CD40 and uses thereof
MX2021014952A (es) Molecula de union especifica para cd73 y uso de la molecula de union.
MX2023006773A (es) Composiciones de agentes de union a antigenos de guanilato ciclasa c (gcc) y metodos de uso de estos.
WO2022006451A3 (en) Compositions and methods for tcr reprogramming using fusion proteins and pd-1 antibodies
MX2023001256A (es) Proteínas que comprenden dominios de unión al antígeno hla-g y sus usos.
WO2016063026A3 (en) Selective nav protein binders